Literature DB >> 9531324

Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10.

B R Lúdvíksson1, M C Sneller, K S Chua, C Talar-Williams, C A Langford, R O Ehrhardt, A S Fauci, W Strober.   

Abstract

Wegener's granulomatosis (WG) is a granulomatous vasculitis that affects the upper respiratory tract, lung, and kidney. Since T cells make up a significant proportion of cells infiltrating granulomatous lesions in WG, we investigated the proliferative response and cytokine profile of T cells from these patients. PBMCs were isolated from 12 patients with active WG, 7 patients with inactive disease, and 12 healthy normal donors. PBMCs from clinically active WG patients exhibited increased proliferation following stimulation with either PMA/ionomycin or anti-CD2 and anti-CD28, when compared with normal donors. In addition, these PBMCs exhibited increased secretion of IFN-gamma, but not of IL-4, IL-5, or IL-10. Furthermore, TNF-alpha production from PBMCs and CD4+ T cells isolated from patients with WG was elevated, when compared with healthy donors. In further studies, we investigated the ability of WG patients' monocytes to produce IL-12 and showed that both inactive and active patients produced increased amounts of IL-12. Finally, the in vitro IFN-gamma production by WG PBMC is inhibited in a dose-dependent manner by exogenous IL-10. These data suggest that T cells from WG patients overproduce IFN-gamma and TNF-alpha, probably due to dysregulated IL-12 secretion, and that IL-10 may therefore have therapeutic implications for this disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531324

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

Review 1.  Perspective on future therapy of vasculitis.

Authors:  D T Boumpas; H D Kritikos; N G Daskalakis
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

Review 2.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

Review 3.  Rare diseases.3: Wegener's granulomatosis.

Authors:  C A Langford; G S Hoffman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

Review 4.  Pathogenesis and treatment of ANCA-associated systemic vasculitis.

Authors:  A D Salama
Journal:  J R Soc Med       Date:  1999-09       Impact factor: 5.344

Review 5.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

6.  Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis.

Authors:  C E Balding; A J Howie; A B Drake-Lee; C O Savage
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

7.  Amphipathic variable region heavy chain peptides derived from monoclonal human Wegener's anti-PR3 antibodies stimulate lymphocytes from patients with Wegener's granulomatosis and microscopic polyangiitis.

Authors:  E Peen; C Malone; C Myers; R C Williams; A B Peck; E Csernok; W L Gross; R Staud
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

8.  Elevated monocytic IL-12 and TNF-alpha production in Wegener's granulomatosis is normalized by cyclophosphamide and corticosteroid therapy.

Authors:  P Lamprecht; G Kumanovics; A Mueller; E Csernok; A Komocsi; A Trabandt; W L Gross; A Schnabel
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

Review 9.  Cellular aspects of vasculitis--T cell-mediated aspects.

Authors:  M E Griffith; C D Pusey
Journal:  Springer Semin Immunopathol       Date:  2001

10.  Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis.

Authors:  Andras Komocsi; Peter Lamprecht; Elena Csernok; Antje Mueller; Konstanze Holl-Ulrich; Ulrike Seitzer; Frank Moosig; Armin Schnabel; Wolfgang Ludwig Gross
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.